These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11547117)

  • 1. Exclusion mapping of major crystallization inhibitors in idiopathic calcium urolithiasis.
    Cailhier JF; Petrucci M; Valiquette L; Guay G; Ouimet D; Bonnardeaux A
    J Urol; 2001 Oct; 166(4):1484-6. PubMed ID: 11547117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis.
    Marengo SR; Chen DH; Kaung HL; Resnick MI; Yang L
    J Urol; 2002 May; 167(5):2192-7. PubMed ID: 11956477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals.
    Ryall RL; Chauvet MC; Grover PK
    BJU Int; 2005 Sep; 96(4):654-63. PubMed ID: 16104927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic urinary stone disease: possible polygenic aetiological factors.
    Watts RW
    QJM; 2005 Apr; 98(4):241-6. PubMed ID: 15781479
    [No Abstract]   [Full Text] [Related]  

  • 5. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
    Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
    J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary calcium oxalate crystal growth inhibitors.
    Worcester EM
    J Am Soc Nephrol; 1994 Nov; 5(5 Suppl 1):S46-53. PubMed ID: 7873744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test.
    Voss S; Hesse A; Zimmermann DJ; Sauerbruch T; von Unruh GE
    J Urol; 2006 May; 175(5):1711-5. PubMed ID: 16600737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells.
    Kumar V; Farell G; Lieske JC
    J Urol; 2003 Jul; 170(1):221-5. PubMed ID: 12796693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inter-alpha-inhibitor: a protein family involved in the inhibition of calcium oxalate crystallization.
    Atmani F; Mizon J; Khan SR
    Scanning Microsc; 1996; 10(2):425-33; discussion 433-4. PubMed ID: 9813621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Tamm-Horsfall protein in a rat nephrolithiasis model.
    Gokhale JA; Glenton PA; Khan SR
    J Urol; 2001 Oct; 166(4):1492-7. PubMed ID: 11547119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both.
    Mo L; Liaw L; Evan AP; Sommer AJ; Lieske JC; Wu XR
    Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1935-43. PubMed ID: 17898038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL; Nakada SY
    Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
    Hassani MA; Hennequin C; Lacour B; Daudon M
    Prog Urol; 2005 Sep; 15(4):650-5. PubMed ID: 16459680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Tamm-Horsfall mucoprotein in calcium oxalate crystallization. N-acetylcysteine--a new therapy for calcium oxalate urolithiasis.
    Fan J; Shen SJ
    Br J Urol; 1994 Sep; 74(3):288-93. PubMed ID: 7953256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the calcium-sensing receptor gene in idiopathic hypercalciuria and calcium nephrolithiasis.
    Petrucci M; Scott P; Ouimet D; Trouvé ML; Proulx Y; Valiquette L; Guay G; Bonnardeaux A
    Kidney Int; 2000 Jul; 58(1):38-42. PubMed ID: 10886547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?
    Kavanagh JP; Laube N
    J Urol; 2006 Feb; 175(2):766-70. PubMed ID: 16407047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary metabolic evaluations in solitary and recurrent stone forming children.
    DeFoor W; Minevich E; Jackson E; Reddy P; Clark C; Sheldon C; Asplin J
    J Urol; 2008 Jun; 179(6):2369-72. PubMed ID: 18433777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis.
    Dey J; Creighton A; Lindberg JS; Fuselier HA; Kok DJ; Cole FE; Hamm L
    J Urol; 2002 Jan; 167(1):169-71. PubMed ID: 11743298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.